Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | HTT | P42858 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 4/20 | 0.35 |
| ▸ | PHGDH | O43175 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 3/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11488582 | 0.83 | ALDH1A1 (0.41) | ALDH1A1HTTKDM4ERAB9ALMNA | |
| SCHEMBL948599 | 0.82 | ALDH1A1 (0.41) | ALDH1A1HTTKDM4ERAB9AMAPT | |
| SCHEMBL14370009 | 0.80 | ALDH1A1 (0.35) | ALDH1A1HTTKDM4ERAB9ALMNA | |
| SCHEMBL2801277 | 0.76 | CASP1 (0.41) | ALDH1A1KDM4ELMNAMAPTNPC1 | |
| SCHEMBL952143 | 0.72 | ELANE (0.39) | ALDH1A1KDM4EMAPTNPC1TP53 | |
| SCHEMBL27546454 | 0.72 | ELANE (0.39) | ALDH1A1KDM4EMAPTNPC1TP53 | |
| SCHEMBL16018328 | 0.69 | HTT (0.40) | ALDH1A1HTTKDM4ELMNAMAPT | |
| SCHEMBL6852036 | 0.69 | ELANE (0.54) | HTTRAB9ANPC1L3MBTL1SMN1; SMN2 | |
| SCHEMBL7330645 | 0.69 | KDM4E (0.46) | ALDH1A1HTTKDM4ELMNAMAPT | |
| SCHEMBL6850665 | 0.69 | F2 (0.55) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7288624-B2 | Inhibitors of interleukin-1β converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-30 | — | — | US | disclosed |
| US-6777431-B2 | ANTICOAGULANTS | CORVAS INTERNATIONAL, INC. | 2004-08-17 | — | — | US | disclosed |
| US-20030092679-A1 | Novel non-convalent thrombin inhibitors | DENDREON PHARMACEUTICALS LLC | 2003-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092679-A1 | Novel non-convalent thrombin inhibitors | F2, SERPINC1, F2RL3 | ALDH1A1 4674/4885HTT 3323/4885KDM4E 3434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.